DBV Technologies exercised all ABSA and BS warrants on January 15 2026, a move announced the following day. The exercise generated €166.7 million in gross proceeds, created 59,657,507 new ordinary shares, and issued 71,005,656 pre‑funded warrants that could raise the total financing to €168.2 million if all warrants are exercised.
The warrants were triggered by the positive topline results from the VITESSE Phase 3 trial, announced on December 16 2025. Those results de‑risked the VIASKIN® Peanut patch program and unlocked the warrants, giving DBV a timely opportunity to secure capital to advance regulatory and commercial plans.
The new capital extends DBV’s cash runway by at least 12 months, providing the resources needed to prepare a Biologics License Application for the VIASKIN® Peanut patch in children aged 4‑7 and to support a potential U.S. launch if regulatory approval is obtained. The financing also underpins the company’s EPIT platform, a core technology that differentiates its product portfolio.
Prior to the raise, Q1 2025 results showed a net loss of $27.1 million and Q3 2025 cash and cash equivalents stood at $69.8 million, underscoring the urgency of the funding. CEO Daniel Tassé said the financing “gives us the runway to bring VIASKIN to patients and to continue advancing our EPIT platform.”
Analysts view the financing as a de‑risking event, noting that the positive VITESSE results and the company’s ability to move forward with a BLA submission reinforce confidence in the VIASKIN® Peanut patch’s regulatory trajectory.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.